Otonomy, Inc. (NASDAQ:OTIC) is reporting third quarter earnings results on Wednesday 4th November 2020, after market close.
The consensus estimates from Thomson Reuters are loss of $ 0.24 per share.
For the full year, analysts predict revenues of $ 0.58 million, while looking forward to loss of $ 1.21 per share.
Previous Quarter Performance
Otonomy, Inc. announced loss for the second quarter of $ 0.37 per share, from the revenue of $ 0.01 million. The quarterly revenues decreased 96.00 percent compared with the same quarter last year. Wall street analysts are predicting, OTIC to report 2Q20 loss of $ 0.39 per share from revenue of $ 0.09 million. The bottom line results beat street analysts by $ 0.02 or 5.13 percent, at the same time, top line results fell short of analysts by $ 0.08 million or 88.89 percent.
Stock Performance
Shares of Otonomy, Inc. traded up $ 0.05 or 1.44 percent on Tuesday, reaching $ 3.53 with volume of 144.80 thousand shares. Otonomy, Inc. has traded high as $ 3.62 and has cracked $ 3.38 on the downward trend
According to the previous trading day, closing price of $ 3.53, representing a 127.45 % increase from the 52 week low of $ 1.53 and a 28.83 % decrease over the 52 week high of $ 4.89.
The company has a market capital of $ 170.24 million and is part of the Healthcare sector and Biotechnology industry.
Conference Call
Otonomy, Inc. will be hosting a conference call at 4:30 PM eastern time on 4th November 2020, to discuss its 3Q20 financial results with the investment community. A live webcast with presentations will be available on the Internet by visiting the Company website www.otonomy.com
Otonomy, Inc., a biopharmaceutical company, develops therapeutics for neurotology in the United States. The company offers OTIPRIO, a ciprofloxacin otic suspension for use during tympanostomy tube placement surgery in pediatric patients. It also develops OTIVIDEX, a sustained-exposure formulation of the steroid dexamethasone in Phase III clinical trial for the treatment of Ménières disease; OTO-313, a sustained-exposure formulation of N-methyl-D-aspartate receptor antagonist gacyclidine, which is in Phase I/II clinical trial to treat tinnitus; and OTO-413, a proprietary formulation of brain-derived neurotrophic factor that is in Phase I/II clinical trial for the repair of cochlear synaptopathy and the treatment of speech-in-noise hearing difficulties.
